West Pharmaceutical

WST

Market cap $18.7B

EXTON, Pa., April 9, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2026 financial results before the market opens on Thursday, April 23, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Align Technology (ALGN) or West Pharmaceutical Services (WST). But which of these two stocks is more attractive to value investors?

West Pharmaceutical expands Dublin facility to boost injectable therapy capacity and strengthen its end-to-end manufacturing platform.

I am shifting capital allocation toward scarcity-driven assets like energy, metals, infrastructure, and defense, as the abundance trade in software faces structural disruption from AI. My TOLL framework prioritizes companies with hard assets, durable competitive moats, and long-duration cash flows that are less vulnerable to AI-driven commoditization. Key investment themes include nuclear utilities (VST, CEG), copper producers (FCX), gold/silver streamers (FNV, WPM), grid/infrastructure suppliers (ETN, FIX), and defense/aerospace leaders (RTX, TDG).

EXTON, Pa., March 31, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West's contract services and is designed to meet growing global demands of its customers' high-volume treatments, including diabetes and obesity.

Dividend Aristocrats, tracked via NOBL, outperformed SPY YTD despite a sharp March pullback, with 44 Aristocrats beating SPY and 17 posting double-digit gains. Momentum, valuation (via dividend yield theory), and projected long-term total return now guide Aristocrat selection, with 39 currently screening as undervalued and offering ≥10% expected annualized returns. Recent dividend increases from CL, GD, LIN, and O bring the 2026 average Aristocrat dividend growth rate to 3.40%, with Realty Income expected to announce further hikes throughout the year.

Investors interested in stocks from the Medical - Dental Supplies sector have probably already heard of Align Technology (ALGN) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?

West Pharmaceutical Services, Inc. (WST) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript

Middle East tensions rattle markets as oil tops $100. Atmos Energy, Colgate-Palmolive and West Pharmaceutical Services stand out as dividend aristocrats for stability.

WST eyes growth from high-value components, GLP-1 drug demand and Annex 1 conversions, but generics destocking and European capacity constraints pose risks.